Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation."

Thrombosis and Haemostasis

Volumn 110, Issue 3, 2013, Pages 493-495

  Diener, Hans Christoph ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; EMBOLISM; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS (TOPIC); NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSIENT ISCHEMIC ATTACK;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DIABETES COMPLICATIONS; FEMALE; HEMORRHAGE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MORPHOLINES; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; STROKE; THIOPHENES; WARFARIN;

EID: 84883215828     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-04-0277     Document Type: Note

References (7)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
2. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
3. Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11: 503-511.
4. Diener HC, Eikelboom J, Connolly SJ, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012; 11: 225-231.
5. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511-1517.
6. Ntaios G, Papavasileiou V, Diener HC, et al. Nonvitamin-k-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43: 3298-3304.
7. Rasmussen LH, Larsen TB, Graungaard T, et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. Br Med J 2012; 345: e7097.